Novel Management and Screening Approaches for Haematological Complications of Gaucher’s Disease

References

• Cox TM, Schofield JP. Gaucher’s disease: clinical features and natural history. Baillieres Clin Haematol. 1997;10:657–689. doi:10.1016/S0950-3536(97)80033-9
   PubMed Web of Science ®Google Scholar
• Grabowski GA. Phenotype, diagnosis, and treatment of Gaucher’s disease. Lancet. 2008;372:1263–1271. doi:10.1016/S0140-6736(08)61522-6
   PubMed Web of Science ®Google Scholar
• Pastores GM, Hughes DA. Gaucher disease. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews^® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2021. July 27, 2000 [updated June 21, 2018].
   Google Scholar
• Stirnemann J, Belmatoug N, Camou F, et al. A review of Gaucher disease pathophysiology, clinical presentation and treatments. Int J Mol Sci. 2017;18:441. doi:10.3390/ijms18020441
   PubMed Web of Science ®Google Scholar
• Nalysnyk L, Rotella P, Simeone JC, et al. Gaucher disease epidemiology and natural history: a comprehensive review of the literature. Hematology. 2017;22:65–73. doi:10.1080/10245332.2016.1240391
   PubMed Web of Science ®Google Scholar
• Baris HN, Cohen IJ, Mistry PK. Gaucher disease: the metabolic defect, pathophysiology, phenotypes and natural history. Pediatr Endocrinol Rev. 2014;12(Suppl 1):72–81.
   Google Scholar
• Grabowski GA, Zimran A, Ida H. Gaucher disease types 1 and 3: phenotypic characterization of large populations from the ICGG Gaucher registry. Am J Hematol. 2015;90(Suppl 1):S12–8. doi:10.1002/ajh.24063
   PubMed Web of Science ®Google Scholar
• Andrade-Campos M, Capablo JL, Fraile JJ, et al. Twenty-five years diagnosing Gaucher’s disease in Spain, what we have learned? Blood. 2018;132(Supplement 1):1110. doi:10.1182/blood-2018-99-115474
   Web of Science ®Google Scholar
• Gordon S, Plüddemann A, Martinez Estrada F. Macrophage heterogeneity in tissues: phenotypic diversity and functions. Immunol Rev. 2014;262:36–55. doi:10.1111/imr.12223
   Web of Science ®Google Scholar
• Boven LA, van Meurs M, Boot RG, et al. Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am J Clin Pathol. 2004;122:359–369. doi:10.1309/BG5VA8JRDQH1M7HN
   PubMed Web of Science ®Google Scholar
• Gören Şahin D, Üsküdar Teke H, Karagülle M, et al. Gaucher cells or pseudo-Gaucher cells: that’s the question. Turk J Haematol. 2014;31:428–429. doi:10.4274/tjh.2014.0019
   Web of Science ®Google Scholar
• Medrano-Engay B, Irun P, Gervas-Arruga J, et al. Iron homeostasis and infIammatory biomarker analysis in patients with type 1 Gaucher disease. Blood Cells Mol Dis. 2014;53:171–175. doi:10.1016/j.bcmd.2014.07.007
   Web of Science ®Google Scholar
• Regenboog M, van Kuilenburg AB, Verheij J, et al. Hyperferritinemia and iron metabolism in Gaucher disease: potential pathophysiological implications. Blood Rev. 2016;30:431–437. doi:10.1016/j.blre.2016.05.003
   Web of Science ®Google Scholar
• Arends M, van Dussen L, Biegstraaten M, Hollak CE. Malignancies and monoclonal gammopathy in Gaucher disease; a systematic review of the literature. Br J Haematol. 2013;161:832–842. doi:10.1111/bjh.12335
   PubMed Web of Science ®Google Scholar
• Limgala RP, Ioanou C, Plassmeyer M, et al. Time of initiating enzyme replacement therapy affects immune abnormalities and disease severity in patients with Gaucher disease. PLoS One. 2016;11:e0168135. doi:10.1371/journal.pone.0168135
   PubMed Web of Science ®Google Scholar
• Mitrovic M, Elezovic I, Miljic P, Suvajdzic N. Acquired von Willebrand syndrome in patients with Gaucher disease. Blood Cells Mol Dis. 2014;52:205–207. doi:10.1016/j.bcmd.2013.11.001
   PubMed Web of Science ®Google Scholar
• Spectre G, Roth B, Ronen G, et al. Platelet adhesion defect in type I Gaucher disease is associated with a risk of mucosal bleeding. Br J Haematol. 2011;153:372–378. doi:10.1111/j.1365-2141.2011.08613.x
   PubMed Web of Science ®Google Scholar
• Mehta A. Gaucher disease: unmet treatment needs. Acta Paediatr. 2008;97:83–87. doi:10.1111/j.1651-2227.2008.00653.x
   Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. PLoS Med. 2021;18:e1003583. doi:10.1371/journal.pmed.1003583
   PubMed Web of Science ®Google Scholar
• Medoff AS, Bayrd ED. Gaucher’s disease in 29 cases: hematologic complications and effect of splenectomy. Ann Intern Med. 1954;40:481–492.
   PubMed Web of Science ®Google Scholar
• Giraldo P, Pérez-López J, Núñez R, et al. Patients with type 1 Gaucher disease in Spain: a cross-sectional evaluation of health status. Blood Cells Mol Dis. 2016;56:23–30. doi:10.1016/j.bcmd.2015.10.001
   PubMed Web of Science ®Google Scholar
• Charrow J, Esplin JA, Gribble TJ, et al. Gaucher disease: recommendations on diagnosis, evaluation, and monitoring. Arch Intern Med. 1998;158:1754–1760. doi:10.1001/archinte.158.16.1754
   PubMed Web of Science ®Google Scholar
• Essabar L, Meskini T, Lamalmi N, et al. Gaucher’s disease: report of 11 cases with review of literature. Pan Afr Med J. 2015;20:18. doi:10.11604/pamj.2015.20.18.4112
   PubMed Web of Science ®Google Scholar
• Niederau C, Häussinger D. Gaucher’s disease: a review for the internist and hepatologist. Hepatogastroenterology. 2000;47:984–997.
   Google Scholar
• Niederau C, Rolfs A, Vom Dahl S, et al. Diagnose und Therapie des Morbus Gaucher. Aktuelle Empfehlungen der deutschen Therapiezentren im Jahr 2000 [Diagnosis and therapy of Gaucher disease. Current recommendations of German therapy centers in the year 2000]. Med Klin (Munich). 2001;96:32–39. doi:10.1007/PL00002150
   Google Scholar
• Belmatoug N, Caubel I, Stirnemann J, Billette de Villemeur T. La maladie de Gaucher [Gaucher’s disease]. J Soc Biol. 2002;196:141–149. doi:10.1051/jbio/2002196020141
   Google Scholar
• Giraldo P, Pocoví M, Pérez-Calvo J, et al. Report of the Spanish Gaucher’s disease registry: clinical and genetic characteristics. Haematologica. 2000;85:792–799.
   PubMed Web of Science ®Google Scholar
• Weinreb NJ, Camelo JS Jr, Charrow J, et al.; International Collaborative Gaucher Group (ICGG) Gaucher Registry (NCT00358943) investigators. Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment. Mol Genet Metab. 132;2021:100–111. doi:10.1016/j.ymgme.2020.12.295
   Web of Science ®Google Scholar
• Zimran A, Altarescu G, Rudensky B, et al. Survey of hematological aspects of Gaucher disease. Hematology. 2005;10:151–156. doi:10.1080/10245330500067181
   PubMed Web of Science ®Google Scholar
• Mistry PK, Batista JL, Andersson HC, et al. Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry. Am J Hematol. 2017;92:929–939. doi:10.1002/ajh.24801
   PubMed Web of Science ®Google Scholar
• Thomas AS, Mehta AB, Hughes DA. Diagnosing Gaucher disease: an on-going need for increased awareness amongst haematologists. Blood Cells Mol Dis. 2013;50:212–217. doi:10.1016/j.bcmd.2012.11.004
   PubMed Web of Science ®Google Scholar
• Hughes D. Gaucher disease: hematologic and oncologic implications. Clin Adv Hematol Oncol. 2011;9:771–772.
   Google Scholar
• Linari S, Castaman G. Hematological manifestations and complications of Gaucher disease. Expert Rev Hematol. 2016;9:51–58. doi:10.1586/17474086.2016.1112732
   PubMed Web of Science ®Google Scholar
• Zimran A, Belmatoug N, Bembi B, et al. Demographics and patient characteristics of 1209 patients with Gaucher disease: descriptive analysis from the Gaucher Outcome Survey (GOS). Am J Hematol. 2018;93:205–212. doi:10.1002/ajh.24957
   Web of Science ®Google Scholar
• Puri RD, Kapoor S, Kishnani PS, et al.; Gaucher Disease Task Force. Diagnosis and management of Gaucher disease in India - consensus guidelines of the Gaucher Disease Task Force of the Society for Indian Academy of Medical Genetics and the Indian Academy of Pediatrics. Indian Pediatr. 2018;55:143–153. doi:10.1007/s13312-018-1249-9
   Web of Science ®Google Scholar
• Hughes DA, Pastores GM. Haematological manifestations and complications of Gaucher disease. Curr Opin Hematol. 2013;20:41–47. doi:10.1097/MOH.0b013e32835a9148
   Web of Science ®Google Scholar
• Andrade-Campos MM, de Frutos LL, Cebolla JJ, et al. Identification of risk features for complication in Gaucher’s disease patients: a machine learning analysis of the Spanish registry of Gaucher disease. Orphanet J Rare Dis. 2020;15:256. doi:10.1186/s13023-020-01520-7
   PubMed Web of Science ®Google Scholar
• Revel-Vilk S, Szer J, Zimran A. Hematological manifestations and complications of Gaucher disease. Expert Rev Hematol. 2021;14:347–354. doi:10.1080/17474086.2021.1908120
   PubMed Web of Science ®Google Scholar
• Wasserstein MP, Caggana M, Bailey SM, et al. The New York pilot newborn screening program for lysosomal storage diseases: report of the first 65,000 infants. Genet Med. 2019;21:631–640. doi:10.1038/s41436-018-0129-y
   PubMed Web of Science ®Google Scholar
• Navarrete-Martínez JI, Limón-Rojas AE, Gaytán-García MJ, et al. Newborn screening for six lysosomal storage disorders in a cohort of Mexican patients: three-year findings from a screening program in a closed Mexican health system. Mol Genet Metab. 2017;121:16–21. doi:10.1016/j.ymgme.2017.03.001
   PubMed Web of Science ®Google Scholar
• Burlina AB, Polo G, Salviati L, et al. Newborn screening for lysosomal storage disorders by tandem mass spectrometry in North East Italy. J Inherit Metab Dis. 2018;41:209–219. doi:10.1007/s10545-017-0098-3
   PubMed Web of Science ®Google Scholar
• Burton BK, Charrow J, Hoganson GE, et al. Screening for lysosomal storage disorders in Illinois: the initial 15-month experience. J Pediatr. 2017;190:130–135. doi:10.1016/j.jpeds.2017.06.048
   PubMed Web of Science ®Google Scholar
• Elliott S, Buroker N, Cournoyer JJ, et al. Pilot study of newborn screening for six lysosomal storage diseases using Tandem Mass Spectrometry. Mol Genet Metab. 2016;118:304–309. doi:10.1016/j.ymgme.2016.05.015
   PubMed Web of Science ®Google Scholar
• Kang L, Zhan X, Gu X, Zhang H. Successful newborn screening for Gaucher disease using fluorometric assay in China. J Hum Genet. 2017;62:763–768. doi:10.1038/jhg.2017.36
   Web of Science ®Google Scholar
• Liao HC, Chiang CC, Niu DM, et al. Detecting multiple lysosomal storage diseases by tandem mass spectrometry–a national newborn screening program in Taiwan. Clin Chim Acta. 2014;431:80–86. doi:10.1016/j.cca.2014.01.030
   PubMed Web of Science ®Google Scholar
• Camargo Neto E, Schulte J, Pereira J, et al. Neonatal screening for four lysosomal storage diseases with a digital microfluidics platform: initial results in Brazil. Genet Mol Biol. 2018;41:414–416. doi:10.1590/1678-4685-gmb-2017-0227
   PubMed Web of Science ®Google Scholar
• Sanders KA, Gavrilov DK, Oglesbee D, et al. A comparative effectiveness study of Newborn screening methods for four lysosomal storage disorders. Int J Neonatal Screen. 2020;6:44. doi:10.3390/ijns6020044
   Web of Science ®Google Scholar
• Málaga DR, Brusius-Facchin AC, Siebert M, et al. Sensitivity, advantages, limitations, and clinical utility of targeted next-generation sequencing panels for the diagnosis of selected lysosomal storage disorders. Genet Mol Biol. 2019;42(1 suppl 1):197–206. doi:10.1590/1678-4685-gmb-2018-0092
   Web of Science ®Google Scholar
• Lei K, Zhao Y, Sun L, et al. A pilot screening of high-risk Gaucher disease children using dried blood spot methods in Shandong province of China. Orphanet J Rare Dis. 2018;13:48. doi:10.1186/s13023-018-0782-x
   Web of Science ®Google Scholar
• Huang Y, Jia X, Tang C, et al. High risk screening for Gaucher disease in patients with splenomegaly and/or thrombocytopenia in China: 55 cases identified. Clin Chim Acta. 2020;506:22–27. doi:10.1016/j.cca.2020.03.016
   Web of Science ®Google Scholar
• Motta I, Filocamo M, Poggiali E, et al.; Splenomegaly Gaucher Disease study group. A multicentre observational study for early diagnosis of Gaucher disease in patients with Splenomegaly and/or Thrombocytopenia. Eur J Haematol. 2016;96:352–359. doi:10.1111/ejh.12596
   Web of Science ®Google Scholar
• Miyamoto T, Iino M, Komorizono Y, et al. Screening for Gaucher disease using dried blood spot tests: a Japanese Multicenter, Cross-sectional Survey. Intern Med. 2021;60:699–707. doi:10.2169/internalmedicine.5064-20
   Web of Science ®Google Scholar
• Andrade-Campos M, Alfonso P, Irun P, et al. Diagnosis features of pediatric Gaucher disease patients in the era of enzymatic therapy, a national-base study from the Spanish Registry of Gaucher Disease. Orphanet J Rare Dis. 2017;12:84. doi:10.1186/s13023-017-0627-z
   PubMed Web of Science ®Google Scholar
• Giraldo P, López de Frutos L, Cebolla JJ. Biomarker combination is necessary for the assessment of Gaucher disease? Ann Transl Med. 2018;6(Suppl 1):S81. doi:10.21037/atm.2018.10.69
   Web of Science ®Google Scholar
• Fuller M, Tucker JN, Lang DL, et al. Screening patients referred to a metabolic clinic for lysosomal storage disorders. J Med Genet. 2011;48:422–425. doi:10.1136/jmg.2010.088096
   PubMed Web of Science ®Google Scholar
• Tang C, Jia X, Tang F, et al. Detection of glucosylsphingosine in dried blood spots for diagnosis of Gaucher disease by LC-MS/MS. Clin Biochem. 2021;87:79–84. doi:10.1016/j.clinbiochem.2020.10.011
   PubMed Web of Science ®Google Scholar
• Mistry PK, Cappellini MD, Lukina E, et al. A reappraisal of Gaucher disease-diagnosis and disease management algorithms. Am J Hematol. 2011;86:110–115. doi:10.1002/ajh.21888
   PubMed Web of Science ®Google Scholar
• Di Rocco M, Andria G, Deodato F, et al. Early diagnosis of Gaucher disease in pediatric patients: proposal for a diagnostic algorithm. Pediatr Blood Cancer. 2014;61:1905–1909. doi:10.1002/pbc.25165
   PubMed Web of Science ®Google Scholar
• Mehta A, Kuter DJ, Salek SS, et al. Presenting signs and patient co-variables in Gaucher disease: outcome of the Gaucher Earlier Diagnosis Consensus (GED-C) Delphi initiative. Intern Med J. 2019;49:578–591. doi:10.1111/imj.14156
   PubMed Web of Science ®Google Scholar
• Billett HH, Rizvi S, Sawitsky A. Coagulation abnormalities in patients with Gaucher’s disease: effect of therapy. Am J Hematol. 1996;51:234–236. doi:10.1002/(SICI)1096-8652(199603)51:3<234::AID-AJH9>3.0.CO;2-Y
   PubMed Web of Science ®Google Scholar
• Hollak CE, Levi M, Berends F, et al. Coagulation abnormalities in type 1 Gaucher disease are due to low-grade activation and can be partly restored by enzyme supplementation therapy. Br J Haematol. 1997;96:470–476. doi:10.1046/j.1365-2141.1997.d01-2076.x
   PubMed Web of Science ®Google Scholar
• Katz K, Tamary H, Lahav J, et al. Increased operative bleeding during orthopaedic surgery in patients with type I Gaucher disease and bone involvement. Bull Hosp Jt Dis. 1999;58:188–190.
   PubMedGoogle Scholar
• Giona F, Palumbo G, Amendola A, et al. Platelet function and coagulation abnormalities in type 1 Gaucher disease patients: effects of enzyme replacement therapy (ERT). J Thromb Haemost. 2006;4:1831–1833. doi:10.1111/j.1538-7836.2006.02037.x
   PubMed Web of Science ®Google Scholar
• Deghady A, Marzouk I, El-Shayeb A, Wali Y. Coagulation abnormalities in type 1 Gaucher disease in children. Pediatr Hematol Oncol. 2006;23:411–417. doi:10.1080/08880010600623232
   PubMed Web of Science ®Google Scholar
• Mitrovic M, Antic D, Elezovic I, et al. Haemostatic abnormalities in treatment-naïve patients with type 1 Gaucher’s disease. Platelets. 2012;23:143–149. doi:10.3109/09537104.2011.597526
   PubMed Web of Science ®Google Scholar
• Givol N, Goldstein G, Peleg O, et al. Thrombocytopenia and bleeding in dental procedures of patients with Gaucher disease. Haemophilia. 2012;18:117–121. doi:10.1111/j.1365-2516.2011.02540.x
   PubMed Web of Science ®Google Scholar
• Komninaka V, Repa K, Marinakis T, et al. Platelet function defects in patients with Gaucher disease on long term ERT- implications for evaluation at bleeding challenges. Blood Cells Mol Dis. 2020;80:102371. doi:10.1016/j.bcmd.2019.102371
   PubMed Web of Science ®Google Scholar
• Rosenbaum H. Hemorrhagic aspects of Gaucher disease. Rambam Maimonides Med J. 2014;5(4):e0039. doi:10.5041/RMMJ.10173
   PubMedGoogle Scholar
• Mitrovic M, Elezovic I, Grujicic D, et al. Complex haemostatic abnormalities as a cause of bleeding after neurosurgery in a patient with Gaucher disease. Platelets. 2015;26:260–262. doi:10.3109/09537104.2014.903471
   PubMed Web of Science ®Google Scholar
• Clarkson CP, Magann EF, Siddique SA, Morrison JC. Hematological complications of Gaucher’s disease in pregnancy. Mil Med. 1998;163:499–501. doi:10.1093/milmed/163.7.499
   Web of Science ®Google Scholar
• Granovsky-Grisaru S, Belmatoug N, Vom Dahl S, et al. The management of pregnancy in Gaucher disease. Eur J Obstet Gynecol Reprod Biol. 2011;156:3–8. doi:10.1016/j.ejogrb.2010.12.024
   PubMed Web of Science ®Google Scholar
• Rosenbaum H. Management of women with Gaucher disease in the reproductive age. Thromb Res. 2015;135(Suppl 1):S49–51. doi:10.1016/S0049-3848(15)50443-X
   PubMed Web of Science ®Google Scholar
• Hollak CE, Maas M, Aerts JM. Clinically relevant therapeutic endpoints in type I Gaucher disease. J Inherit Metab Dis. 2001;24(Suppl 2):97–105;87–8. doi:10.1023/A:1012492429191
   Web of Science ®Google Scholar
• Pastores GM, Weinreb NJ, Aerts H, et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol. 2004;41(4 Suppl 5):4–14. doi:10.1053/j.seminhematol.2004.07.009
   PubMed Web of Science ®Google Scholar
• Weinreb NJ, Finegold DN, Feingold E, et al. Evaluation of disease burden and response to treatment in adults with type 1 Gaucher disease using a validated disease severity scoring system (DS3). Orphanet J Rare Dis. 2015;10:64. doi:10.1186/s13023-015-0280-3
   Web of Science ®Google Scholar
• Biegstraaten M, Cox TM, Belmatoug N, et al. Management goals for type 1 Gaucher disease: an expert consensus document from the European working group on Gaucher disease. Blood Cells Mol Dis. 2018;68:203–208. doi:10.1016/j.bcmd.2016.10.008
   PubMed Web of Science ®Google Scholar
• Shemesh E, Deroma L, Bembi B, et al. Enzyme replacement and substrate reduction therapy for Gaucher disease. Cochrane Database Syst Rev. 2015;3:CD010324.
   Google Scholar
• Mankin HJ, Trahan CA, Barnett NA, et al. A questionnaire study for 128 patients with Gaucher disease. Clin Genet. 2006;69:209–217. doi:10.1111/j.1399-0004.2006.00573.x
   PubMed Web of Science ®Google Scholar
• Piran S, Roberts A, Patterson MA, Amato D. The clinical course of untreated Gaucher disease in 22 patients over 10 years: hematological and skeletal manifestations. Blood Cells Mol Dis. 2009;43:289–293. doi:10.1016/j.bcmd.2009.08.002
   PubMed Web of Science ®Google Scholar
• Gielchinsky Y, Elstein D, Green R, et al. High prevalence of low serum vitamin B12 in a multi-ethnic Israeli population. Br J Haematol. 2001;115:707–709. doi:10.1046/j.1365-2141.2001.03156.x
   PubMed Web of Science ®Google Scholar
• Wine E, Yaniv I, Cohen IJ. Hyperimmunoglobulinemia in pediatric-onset type 1 Gaucher disease and effects of enzyme replacement therapy. J Pediatr Hematol Oncol. 2007;29:451–457. doi:10.1097/MPH.0b013e31806451d3
   Web of Science ®Google Scholar
• Sender SU, Limgala RP, Ivanova MM, et al. Persistent immune alterations and comorbidities in splenectomized patients with Gaucher disease. Blood Cells Mol Dis. 2016;59:8–15. doi:10.1016/j.bcmd.2016.02.003
   Web of Science ®Google Scholar
• Gervas-Arruga J, Cebolla JJ, de Blas I, et al. The influence of genetic variability and proinflammatory status on the development of bone disease in patients with Gaucher disease. PLoS One. 2015;10(5):e0126153. doi:10.1371/journal.pone.0126153
   Web of Science ®Google Scholar
• Pandey MK, Burrow TA, Rani R, et al. Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease. Nature. 2017;543:108–112. doi:10.1038/nature21368
   Web of Science ®Google Scholar
• Shiran A, Brenner B, Laor A, Tatarsky I. Increased risk of cancer in patients with Gaucher disease. Cancer. 1993;72:219–224. doi:10.1002/1097-0142(19930701)72:1<219::AID-CNCR2820720139>3.0.CO;2-Y
   PubMed Web of Science ®Google Scholar
• Reardon M, Cotter P, Kealy WF, Duggan PF. Gaucher’s disease with haematological complications. Ir Med J. 1993;86:39–40.
   Google Scholar
• de Lonlay P, Fenneteau O, Touati G, et al. Manifestations hématologiques dans les erreurs innées du métabolisme [Hematologic manifestations of inborn errors of metabolism]. Arch Pediatr. 2002;9:822–835. doi:10.1016/S0929-693X(02)00005-2
   Web of Science ®Google Scholar
• Elias AF, Johnson MR, Boitnott JK, Valle D. Neonatal cholestasis as initial manifestation of type 2 Gaucher disease: a continuum in the spectrum of early onset Gaucher disease. JIMD Rep. 2012;5:95–98.
   Google Scholar
• Vom Dahl S, Mengel E. Lysosomal storage diseases as differential diagnosis of hepatosplenomegaly. Best Pract Res Clin Gastroenterol. 2010;24:619–628. doi:10.1016/j.bpg.2010.09.001
   Web of Science ®Google Scholar
• Rosenbloom BE, Weinreb NJ, Zimran A, et al. Gaucher disease and cancer incidence: a study from the Gaucher Registry. Blood. 2005;105:4569–4572. doi:10.1182/blood-2004-12-4672
   PubMed Web of Science ®Google Scholar
• Zimran A, Liphshitz I, Barchana M, et al. Incidence of malignancies among patients with type I Gaucher disease from a single referral clinic. Blood Cells Mol Dis. 2005;34:197–200. doi:10.1016/j.bcmd.2005.03.004
   PubMed Web of Science ®Google Scholar
• Costello R, O’Callaghan T, Baccini V, Sébahoun G. Aspects hématologiques de la maladie de Gaucher [Hematological aspects of Gaucher disease]. Rev Med Interne. 2007;28(Suppl 2):S176–9. doi:10.1016/S0248-8663(07)78877-X
   Google Scholar
• de Fost M, Vom Dahl S, Weverling GJ, et al. Increased incidence of cancer in adult Gaucher disease in Western Europe. Blood Cells Mol Dis. 2006;36:53–58. doi:10.1016/j.bcmd.2005.08.004
   PubMed Web of Science ®Google Scholar
• Taddei TH, Kacena KA, Yang M, et al. The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk. Am J Hematol. 2009;84:208–214. doi:10.1002/ajh.21362
   PubMed Web of Science ®Google Scholar
• Lo SM, Stein P, Mullaly S, et al. Expanding spectrum of the association between Type 1 Gaucher disease and cancers: a series of patients with up to 3 sequential cancers of multiple types–correlation with genotype and phenotype. Am J Hematol. 2010;85:340–345. doi:10.1002/ajh.21684
   PubMed Web of Science ®Google Scholar
• Weinreb NJ, Lee RE. Causes of death due to hematological and non-hematological cancers in 57 US patients with type 1 Gaucher Disease who were never treated with enzyme replacement therapy. Crit Rev Oncog. 2013;18:177–195. doi:10.1615/CritRevOncog.2013005921
   PubMedGoogle Scholar
• Weinreb NJ, Barbouth DS, Lee RE. Causes of death in 184 patients with type 1 Gaucher disease from the United States who were never treated with enzyme replacement therapy. Blood Cells Mol Dis. 2018;68:211–217. doi:10.1016/j.bcmd.2016.10.002
   PubMed Web of Science ®Google Scholar
• Mistry PK, Taddei T, Vom Dahl S, Rosenbloom BE. Gaucher disease and malignancy: a model for cancer pathogenesis in an inborn error of metabolism. Crit Rev Oncog. 2013;18:235–246. doi:10.1615/CritRevOncog.2013006145
   PubMedGoogle Scholar
• Rodic P, Pavlovic S, Kostic T, et al. Gammopathy and B lymphocyte clonality in patients with Gaucher type I disease. Blood Cells Mol Dis. 2013;50:222–225. doi:10.1016/j.bcmd.2012.11.012
   PubMed Web of Science ®Google Scholar
• Cox TM, Rosenbloom BE, Barker RA. Gaucher disease and comorbidities: b-cell malignancy and parkinsonism. Am J Hematol. 2015;90(Suppl 1):S25–8. doi:10.1002/ajh.24057
   PubMed Web of Science ®Google Scholar
• Nair S, Branagan AR, Liu J, et al. Clonal immunoglobulin against lysolipids in the origin of myeloma. N Engl J Med. 2016;374:555–561. doi:10.1056/NEJMoa1508808
   PubMed Web of Science ®Google Scholar
• Nair S, Bar N, Xu ML, et al. Glucosylsphingosine but not Saposin C, is the target antigen in Gaucher disease-associated gammopathy. Mol Genet Metab. 2020;129:286–291. doi:10.1016/j.ymgme.2020.01.009
   PubMed Web of Science ®Google Scholar
• Ranade A, Chintapatla R, Varma M, Sandhu G. Hematologic manifestations and leukemia in Gaucher’s disease. Clin Adv Hematol Oncol. 2013;11:253–255.
   Google Scholar
• Shvidel L, Hurwitz N, Shtalrid M, et al. Complex IgA gammopathy in Gaucher’s disease. Leuk Lymphoma. 1995;20:165–168. doi:10.3109/10428199509054770
   PubMed Web of Science ®Google Scholar
• Martinez-Redondo C, Ortuño FJ, Lozano ML, et al. IgM monoclonal component associated with type I Gaucher disease resolved after enzyme replacement therapy: a case report. J Inherit Metab Dis. 2009;32(Suppl 1):S265–7. doi:10.1007/s10545-009-1207-8
   Web of Science ®Google Scholar
• Perales M, Cervantes F, Cobo F, Montserrat E. Non-Hodgkin’s lymphoma associated with Gaucher’s disease. Leuk Lymphoma. 1998;31:609–612. doi:10.3109/10428199809057621
   PubMed Web of Science ®Google Scholar
• Shvidel L, Sigler E, Shtalrid M, et al. Parotid gland involvement, the presenting sign of high grade non-Hodgkin lymphoma in two patients with Gaucher disease and sicca syndrome. J Inherit Metab Dis. 2007;30:825. doi:10.1007/s10545-007-0610-2
   PubMed Web of Science ®Google Scholar
• Zimran A, Ruchlemer R, Revel-Vilk S. A patient with Gaucher disease and plasma cell dyscrasia: bidirectional impact. Hematology Am Soc Hematol Educ Program. 2020;2020:389–394. doi:10.1182/hematology.2020000123
   PubMed Web of Science ®Google Scholar
• Monge J, Chadburn A, Gergis U. Synchronous multiple myeloma and Gaucher disease. Hematol Oncol Stem Cell Ther. 2020;13:42–45. doi:10.1016/j.hemonc.2019.07.001
   PubMedGoogle Scholar
• Hawkesford MP, Bowey AJ, Rao J, Meara NJ. Synchronous presentation of Gaucher disease and solitary plasmacytoma with progression to multiple myeloma. Scott Med J. 2011;56:236. doi:10.1258/smj.2011.011178
   Google Scholar
• Kim MJ, Suh JT, Lee HJ, et al. Simultaneous detection of Gaucher’s disease and renal involvement of non-Hodgkin’s lymphoma: the first Asian case report and a review of literature. Ann Clin Lab Sci. 2012;42:293–301.
   Web of Science ®Google Scholar
• Haliloglu M, Hoffer FA, Haight AE, Cunningham JM. Budd-Chiari syndrome caused by Gaucher’s disease. Pediatr Radiol. 1999;29:908–910. doi:10.1007/s002470050723
   Web of Science ®Google Scholar
• Miri-Moghaddam E, Velayati A, Naderi M, et al. Coinheritance of Gaucher disease and α-thalassemia resulting in confusion between two inherited hematologic diseases. Blood Cells Mol Dis. 2011;46:88–91. doi:10.1016/j.bcmd.2010.08.007
   Web of Science ®Google Scholar
• Kose MD, Canda E, Kağnıcı M, et al. Coexistence of Gaucher disease and severe congenital neutropenia. Blood Cells Mol Dis. 2019;76:1–6. doi:10.1016/j.bcmd.2018.07.001
   Web of Science ®Google Scholar
• Lester TJ, Grabowski GA, Goldblatt J, et al. Immune thrombocytopenia and Gaucher’s disease. Am J Med. 1984;77:569–571. doi:10.1016/0002-9343(84)90124-4
   Web of Science ®Google Scholar
• Maity P, Roy S, Das R, et al. Acute myeloid leukemia along with Gaucher disease in a child. Indian J Case Rep. 2021;5:211–213. doi:10.32677/IJCR.2021.v07.i05.012
   Google Scholar
• Petrides PE, leCoutre P, Müller-Höcker J, et al. Coincidence of Gaucher’s disease due to a private mutation and Ph’ positive chronic myeloid leukemia. Am J Hematol. 1998;59:87–90. doi:10.1002/(SICI)1096-8652(199809)59:1<87::AID-AJH17>3.0.CO;2-Z
   Web of Science ®Google Scholar
• Villarrubia J, Rodríguez-Gambarte JD, Abalo L, et al. Gaucher disease and myelodysplastic syndrome with isolated del(5q). Br J Haematol. 2014;165:164. doi:10.1111/bjh.12798
   Google Scholar
• Kubo T, Shimose S, Fujimori J, et al. Extraosseous extension caused by epidural hematoma in Gaucher disease mimicking malignant bone tumor. JIMD Rep. 2014;14:67–70.
   Google Scholar
• Noya M, Andrade-Campos M, Irun P, et al. Gaucher disease and chronic myeloid leukemia: first reported patient receiving enzyme replacement and tyrosine kinase inhibitor therapies simultaneously. Clin Case Rep. 2018;6:887–892. doi:10.1002/ccr3.1460
   Web of Science ®Google Scholar
• Ruchlemer R, Mittelman M, Zimran A. Gaucher disease, myelodysplastic syndrome and ICUS. Blood Cells Mol Dis. 2020;80:102373. doi:10.1016/j.bcmd.2019.102373
   Web of Science ®Google Scholar
• Webb BD, Weinreb NJ, Botti AC, et al. JAK2V617F mutation and myeloproliferative malignancy in a patient with Type 1 Gaucher disease. Blood Cells Mol Dis. 2011;46:103–104. doi:10.1016/j.bcmd.2010.09.007
   Web of Science ®Google Scholar
• Lo SM, Choi M, Liu J, et al. Phenotype diversity in type 1 Gaucher disease: discovering the genetic basis of Gaucher disease/hematologic malignancy phenotype by individual genome analysis. Blood. 2012;119:4731–4740. doi:10.1182/blood-2011-10-386862
   PubMed Web of Science ®Google Scholar
• Hughes D, Cappellini MD, Berger M, et al. Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease. Br J Haematol. 2007;138:676–686. doi:10.1111/j.1365-2141.2007.06701.x
   PubMed Web of Science ®Google Scholar
• Mehta A, Belmatoug N, Bembi B, et al. Exploring the patient journey to diagnosis of Gaucher disease from the perspective of 212 patients with Gaucher disease and 16 Gaucher expert physicians. Mol Genet Metab. 2017;122:122–129. doi:10.1016/j.ymgme.2017.08.002
   PubMed Web of Science ®Google Scholar
• Deriaz S, Serratrice C, Lidove O, et al. Parcours diagnostique des patients atteints de maladie de Gaucher de type 1: enquête auprès de médecins internistes et hématologues [Diagnostic journey of type 1 Gaucher Disease patients: a survey including internists and hematologists]. Rev Med Interne. 2019;40:778–784. doi:10.1016/j.revmed.2019.07.011
   Web of Science ®Google Scholar
• Mistry PK, Sadan S, Yang R, et al. Consequences of diagnostic delays in type 1 Gaucher disease: the need for greater awareness among hematologists-oncologists and an opportunity for early diagnosis and intervention. Am J Hematol. 2007;82:697–701. doi:10.1002/ajh.20908
   PubMed Web of Science ®Google Scholar
• Barth BM, Shanmugavelandy SS, Tacelosky DM, et al. Gaucher’s disease and cancer: a sphingolipid perspective. Crit Rev Oncog. 2013;18:221–234. doi:10.1615/CritRevOncog.2013005814
   PubMedGoogle Scholar
• Murugesan V, Chuang W-L, Liu J, et al. Glucosylsphingosine is a key biomarker of Gaucher disease. Am J Hematol. 2016;91(11):1082–1089. doi:10.1002/ajh.24491
   PubMed Web of Science ®Google Scholar